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>^ The appearance of an adrenocorticotropic hormone (ACTH)-producing tumor after bilateral adrenalectomy for 
Cushing disease was first described by Nelson in 1958. The syndrome that now bears his name was characterized by 
hyperpigmentation, a sellar mass, and increased plasma ACTH levels. The treatment of Cushing disease has changed 
drastically since the 1950s, when the choice was adrenalectomy. Thus, the occurrence, diagnosis, and treatment of 
Nelson syndrome have changed as well. In the modern era of high-resolution neuroimaging, transsphenoidal microneu­
rosurgery, and stereotactic radiosurgery, Nelson syndrome has become a rare entity. The authors describe the history 
of the diagnosis and treatment of Nelson syndrome. In light of the changes described, the authors believe this disease 
must be reevaluated in the contemporary era and a modern paradigm adopted. (DOI: 10.3171/FOC-07/09/E12)
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n e u r o su r g e r y  h isto r y
I n  1958, Nelson et al.72 first described the appearance of 
an ACTH-producing tumor after bilateral adrenalecto­
my for Cushing disease. Dr. Don H. Nelson (Fig. 1) 
was a fellow in endocrinology and had already done con­
siderable basic research in adrenal physiology when he ini­
tially reported the syndrome that now bears his name. In the 
original paper, the authors indicated that the syndrome was 
characterized by hyperpigmentation, sellar mass demon­
strated by an enlarged sella turcica on skull radiographs, 
and increased plasma ACTH levels.72 Two years later, Nel­
son and colleagues73 had compiled the information ob­
tained in nine additional patients with the same characteris­
tics and findings as the patient in the initial case 
description. This clinical syndrome was initially known as 
postadrenalectomy syndrome but by 1962 became known 
as Nelson syndrome.56 Although the early definitions of 
this syndrome are paramount in the history of Nelson syn­
drome, the complete story involves the history of the treat­
ment and diagnosis of Cushing disease and Dr. Nelson’s 
contributions to the fields of endocrinology and neuro­
surgery.
Abbreviations used in this paper: ACTH = adrenocorticotropic 
hormone; MR = magnetic resonance.
H is t o r y  o f  C u s h in g  D is e a s e
The earliest published link between the clinical condition 
caused by hypercortisolemia and the adrenal gland was 
written by Guthrie and d’Este in 1907.35 Two years later, in 
an oration entitled “The hypophysis cerebri,” Cushing25 
began to explain the endocrinological functions of the pitu­
itary gland. At this early date, acromegaly was known to be 
caused by a pituitary tumor, but it was not known that 
hypercortisolemia had a similar cause. In 1912, Cushing26 
described his patient, Miss M. G., in his book, The Pituitary 
Body and Its Disorders. Cushing hypothesized that, as in 
acromegaly, the hypercortisolemic syndrome might have 
been due to “a primary malady of the ductless glands.” Two 
years later, in 1914, Sargent removed an adrenal tumor in a 
patient of Dr. Gordon Holmes’, thereby curing the patient 
of this disease and establishing a definitive link between 
hypercortisolemia and adrenal tumors.41
Although a link between hypercortisolemia and adrenal 
tumors was apparent, cases of the hypercortisolemic syn­
drome in which an adrenal tumor was absent were being 
published as early as 1924.4144 This included, in 1926, We­
ber’s case report91 of a patient with the hypercortisolemic 
syndrome and a pituitary tumor, which, however, went 
without notice. Additional reports followed, and, in 1930, 
Viennese pathologist Julius Bauer7 published the case of a
Neurosurg. Focus /  Volume 23 /  September, 2007 1
M. Hornyak et al.
F ig. 1. Recent photograph of Dr. Don H. Nelson, M.D.
patient with hypercortisolemic syndrome without evidence 
of adrenal disease. Cushing read Bauer’s report and recom­
mended that he reexamine the pituitary gland. The speci­
men was found to have a basophilic pituitary tumor.663 At 
about the same time, Cushing published his landmark work 
on basophilic adenomas of the pituitary body24 and the clin­
ical syndrome of hypercortisolemia, which soon came to be 
known as “Cushing syndrome.”12 
Despite the mounting evidence linking hypercortisol- 
emia and pituitary tumors,64 microadenomas were difficult 
to diagnose, and transsphenoidal surgery was not popular at 
this time. Thus, the condition was usually considered to be 
a metabolic disorder caused by increased adrenal gland 
hormone secretion.2 Additional doubts regarding the link 
between hypercortisolemia and pituitary tumors developed 
after the authors of an autopsy study reported in 1935 that 
7% of normal (nonhypercortisolemic) pituitary specimens 
contained a basophil adenoma.22 A similar syndrome was 
found in a patient with a tumor of the thymus, which added 
to the confusion among the medical establishment.53 An 
antipituitary camp, led by Kepler,51 maintained the belief 
that the only cause of Cushing syndrome was adrenal dis­
ease. In fact, it was not until 1950, when Bauer6 published 
his paper, “The so-called Cushing’s syndrome,” that a real 
distinction was made between hypercortisolism caused by 
adrenal disease and that caused by a pituitary tumor. Bauer 
wrote that “Cushing’s disease, therefore, is the association 
of the known clinical syndrome with ‘pituitary baso­
philism.’ Hence it is this association not the clinical syn­
drome that should bear the eponym ‘Cushing’s disease,’” 
but the distinction was not widely accepted until 1972.9
Because of the controversy and limited understanding of 
pituitary physiology and disease, adrenalectomy was most 
often the primary treatment of Cushing syndrome at the 
time Nelson and colleagues initially described the syn­
drome of ACTH hypersecretion. Pituitary surgery was usu­
ally reserved for cases involving visual loss and was per­
formed almost exclusively with craniotomy. At that time, it 
was known that Cushing syndrome was attributable to 
excess adrenal steroids in the blood,47 that this excess was 
unhealthy, and that adrenalectomy improved the clinical 
syndrome and extended the life expectancy of patients with 
this disease. Although there are scattered reports of cases of 
Cushing disease that were successfully treated with pitu­
itary surgery (the earliest in 1933 by Dr. Naffziger58), pitu­
itary surgery undertaken to treat endocrinological disorders 
was not truly accepted until after transsphenoidal micro­
surgery was reintroduced to the neurosurgical community 
by Jules Hardy in 1971,31 and Tyrrell et al.90 and Salassa et 
al.84 reported the cure of hypercortisolemia with the 
removal of microadenomas in their respective surgical 
series of 1978.
H is t o r y  o f  N e ls o n  S y n d r o m e
Until the 1950s, only rather primitive mechanisms were 
available for evaluating adrenal cortical function. Despite 
the fact that Dr. Thomas Addison1 had described the syn­
drome of adrenal insufficiency in 1855, little was known 
about the hormones involved. While he was a research fel­
low, and later as a postdoctoral fellow at the University of 
Utah in the 1940s, Nelson and his colleagues working in 
Leo Samuels’s laboratory endeavored to discover and 
quantify the adrenal steroids in human blood and serum.89 
The specific steroid to be measured remained unknown 
until 1953.83 In 1950, Nelson and Samuels (Fig. 2) pub­
lished a paper in which they described the process for iso­
lating a steroid hormone from the blood of dogs.74 The 
availability of the “Nelson-Samuels” method allowed the 
accelerated pursuit of the physiology of adrenocortical se- 
cretions,1011'3375 including the ability to measure cortico­
steroids in human blood.76 Nelson was drafted into military 
service in 1952 and continued his research at the Naval 
Medical Research Institute in Bethesda. He continued to 
study adrenal physiology, and in 1955 he, along with his 
colleague David Hume, reported a method they had devel­
oped to determine the concentration of ACTH in human 
serum.71 This test was a bioassay in which they used hypo- 
physectomized dogs. It was rather crude by modern stan­
dards, but significantly elevated levels of ACTH could be 
determined. Nelson then used this assay while serving as a 
house officer and research fellow at the Peter Bent Brigham 
Hospital in Boston to study the physiology in Cushing syn­
drome, especially in cases in which no pituitary or adrenal 
tumor could be found. This was the only assay available to 
measure ACTH, and it was used in the first reported case 
of hyperpigmentation, elevated serum ACTH level, and 
pituitary tumor as well as visual loss in a patient who had 
undergone adrenalectomy for Cushing syndrome. It was 
this postadrenalectomy syndrome that later became known 
as Nelson syndrome (the pituitary tumor was often called a 
Nelson tumor).
In 1958, Nelson and colleagues72 reported in the New
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Fig. 2. Photograph of Dr. Nelson (center) and Dr. Leo Samuels (left), circa 1950, in the biochemistry laboratory at the 
University of Utah.
England Journal o f Medicine (Fig. 3) the case of their 33- 
year-old woman, “C.R.” She had initially presented in 1954 
with a 1-year history of nervousness, weakness, leg cramps, 
amenorrhea, acne, hirsutism, deepened voice, abdominal 
striae, polydipsia, and polyuria. On physical examination, 
she was observed to be obese, with a moon face, acne, mild 
hirsutism, and multiple ecchymoses and abdominal striae. 
She was hypertensive, her visual fields were normal, and 
her pituitary fossa size was “at the upper limits of normal” 
on a skull x-ray film. Laboratory studies revealed that she 
had glycosuria and hyperglycemia as well as an elevated 
level of 17-hydroxycorticosteroids in her urine. One month 
after her initial presentation, the patient underwent bilater­
al adrenalectomy. Her adrenal glands were normal in 
weight, but hyperplasia was demonstrated histologically. 
Postoperatively, she was placed on a daily regimen of 50 
mg of cortisone. After 2 months, her symptoms had re­
solved, her endocrinological levels were normal, and she 
began to menstruate normally. Two years later, she com­
plained of menorrhagia and cutaneous pigmentation, but no 
other abnormalities were found, and her serum glucose 
level remained normal.
in 1957, 3 years after her initial presentation, the patient 
began to suffer renewed amenorrhea and progressive loss 
of vision in her left eye. On examination, her skin was 
found to be deeply pigmented (Fig. 4), and she had a near­
ly complete bitemporal hemianopsia. Examination of labo­
ratory studies showed that the level of 17-hydroxycortico- 
steroids was normal, but the level of ACTH exceeded 200 
mU/100 ml (normal levels were undetectable using the 
Nelson-Hume method). A radiographic workup, including
skull radiographs, laminagrams, and a fractional air study, 
now demonstrated expansion of the sella turcica with 
destruction of the dorsum sellae and the presence of a 
suprasellar tumor. Radiotherapy was initiated, but after 24 
treatments hemorrhage into the tumor suddenly occurred. 
Because of the apoplexy, the patient was taken to the oper­
ating room where she underwent urgent decompression via 
craniotomy. A soft, hemorrhagic tumor was resected with­
out complication, and she recovered well. Her vision im­
proved, and her ACTH level became undetectable. She 
underwent monitoring for an additional 18 weeks. During 
this time, her cutaneous pigmentation subsided (Fig. 4) and 
her ACTH remained low, similar to that of other patients 
with hypoadrenocorticism.11
In discussing this case, Nelson first debated the possibil­
ity of two causes of Cushing syndrome: one of adrenal and 
one of pituitary origin. He stated that a pituitary tumor 
should elevate the serum ACTH level but admitted that his 
“methods for the determination of ACTH in plasma are 
generally not sensitive enough” to determine moderately 
increased levels. He also surmised that the patient might 
have had an ACTH-secreting pituitary tumor and that “the 
removal of the adrenal glands may have acted as a stimulus 
to the pituitary gland, with growth of the tumor and 
increased secretion of ACTH resulting.” Finally, he con­
cluded that “development of a pituitary tumor is a possible 
sequela of bilateral adrenalectomy for Cushing’s syn­
drome.”
Because many adrenalectomies were being performed, it 
became increasingly evident that, in a certain population of 
patients, adrenalectomy caused the clinical syndrome of
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ACTH-PRODUCING TUMOR OF THE PITUITARY GLAND*
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THE association of adrenal hyperplasia with baso­
phil tumors of the pituitary gland was first sug-
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l by Cushing.1 This type of tumor has since 
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syndrome, but no demonstration of elevated levels of 
ACTH has been rej>orted in the plasma of patients 
with this condition. The case described below is that 
of a patient who, three years after bilateral adrenalec­
tomy for hypcradrcnocorticism, was found to have 
a chromophobe tumor of the pituitary gland that 
was sccrcling large quantities of ACTH.
C ase R epo rt
C.R. (P.B.B.H. 90410), a 33-year-old married woman of 
Italian extraction, was first admitted to the Peter Bent Brig­
ham Hospital on August 17, 1954 The family and past 
histories were nonconinbutnry. Two pregnancies 9 and 10 
year* previously had been essentially normal. Presenting 
symptom' (from 1 to 12 months in duration) included nerv* 
outness, weakness, leg cramps, amenorrhea, acne, hirsutism, 
deepened voice, obesity, rounding of the face, increased 
bruisahility, abdominal striae, polydipsia and polyuria.
F ig. 3. The title page of the case report in which the authors described the initial identified case of the syndrome that 
came to be known as Nelson syndrome.
hyperpigmentation and pituitary tumor (Nelson syndrome). 
It was believed by many that the removal of the adrenal 
glands caused the de novo formation of a pituitary tumor. 
When testing for serum ACTH levels became available,7179 
Nelson was able to report the abnormally high levels of this 
hormone after adrenalectomy.77 By 1960, he had identified 
10 patients with this “post-adrenalectomy” syndrome.73 In 
this second paper on the syndrome (Fig. 5), Nelson made 
three notable observations. First, he discovered the sup- 
pressibility of ACTH secretion in patients with pituitary tu­
mors after they were given hydrocortisone therapy. Second, 
he described a patient who suffered from Cushing syn­
drome and was found to have an elevated ACTH level but 
no evidence of a pituitary tumor. This patient underwent a 
partial adrenalectomy, which led to a remission of the 
Cushing syndrome, but later suffered recurrence of the 
Cushing syndrome, an increased ACTH level, and a sellar 
tumor but no hyperpigmentation. Nelson himself re­
marked, “It has not been possible with the present technic 
[sic] to detect normal circulating levels of plasma-ACTH, 
and therefore a slight elevation of ACTH above ‘normal’ 
would presumably not be detected by the assay procedure 
used.” Six years later he reported the elevation of ACTH in 
a patient with Cushing syndrome and a pituitary tumor 
before any treatment, foreshadowing the importance of this 
test in the determination of a pituitary source of Cushing 
syndrome.77 Because of their low sensitivity, serum ACTH 
assays could not be used routinely to differentiate pituitary- 
dependent from primary hypercortisolemia until much 
later. Last, Nelson concluded that in patients presenting 
with postadrenalectomy pituitary tumors, the evidence 
“strongly suggests either that the tumor was present prior to 
bilateral adrenalectomy, or that there was some abnormal 
stimulus to the pituitary gland which may have acted to 
produce the pituitary adenoma in these particular cases.” 
This again highlights the uncertainty of the causes of 
Cushing syndrome into the 1960s.
Given the confusion over the cause, the typical treatment 
paradigm for Cushing syndrome of the 1950s and into the
1970s— the use of adrenalectomy— was targeted at the 
final common pathway, regardless of the cause of the hy- 
percortisolemia.28 Irradiation of the sella was sometimes 
performed,65 and hypophysectomy was generally consid­
ered if there were overt signs of a sellar tumor, usually in 
association with a patient’s loss of vision. Given the fact 
that there was still a great deal of controversy surrounding 
the cause of Cushing syndrome, there was no standard of 
care.
Nelson and Cushing Syndromes in the M odern E ra
The development of Nelson syndrome after adrenalecto­
my for Cushing syndrome has been reported in between 8  
and 47% of cases.4'15'16'19'28'30'45'48-50'62'65'68'80'87'95 These numbers 
vary depending on the extent of adrenalectomy, the causes 
of the hypercortisolemia in the treated patients, and the year 
the surgery was performed. As endocrinological' radiolog­
ical/imaging, and neurosurgical advances were made in the 
understanding of and ability to diagnose the causes of 
Cushing syndrome and the modes of therapy, management 
of both Cushing and Nelson syndromes moved into the 
modern era.
The advances in endocrinology led to a better ability to 
diagnose Cushing disease and differentiate its various caus­
es. The first development, as described above, was the abil­
ity to measure corticosteroid76 and ACTH71 levels in human 
blood samples. In part because of the observations made by 
Nelson in 1960, the low- and high-dose dexamethasone 
suppression tests became available to differentiate adrenal- 
and pituitary-dependent hypercortisolemia. Liddle55 report­
ed that the abnormally elevated levels of urinary corticos­
teroids were suppressed in all patients with a known pitu­
itary tumor by high doses of dexamethasone (2 mg every 6 
hours) but not with low doses (0.5 mg every 6 hours). 
Individuals with a known adrenal tumor were completely 
resistant to high and low doses of the drug. This was the 
first reliable test to differentiate among the causes of 
Cushing syndrome. Although this test offered improved
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Fig. 4. Photographs of Patient C.R., the first reported case of 
Nelson syndrome, before (left) and after (right) adrenalectomy for 
Cushing disease. Note the features of Cushing disease preopera- 
tively and the skin pigmentation after. Adapted with permission 
from Nelson DH, The Adrenal Cortex, W . B. Saunders, 1980.
ability for differentiation because it was somewhat specif­
ic, it was not very sensitive, as many patients tested equiv- 
ocally.54 93 Therefore, again following the lead of Nelson, 
the assay for the determination of ACTH in plasma was 
refined. With the production of specific antibodies,31 a ra­
dioimmunoassay could be performed. In 1964, Yalow et 
al.97 reported the results of an assay for ACTH that required 
less than 0.2  ml of serum and had a sensitivity as low as 
0.06 mU/100 ml, approximately 100-fold more sensitive 
than Nelson’s bioassay.77 This allowed the detection of 
mildly elevated ACTH levels that could be caused by a 
pituitary microadenoma. With the advent of stimulation 
testing with corticotropin-releasing factor, the ability to dis­
tinguish the different causes of Cushing syndrome became 
even more widely available.67
Several advances in radiography and neuroimaging also 
led to a change in the differential diagnosis of Cushing syn­
drome. A patient with Cushing syndrome or hyperpigmen­
tation after adrenalectomy was typically screened with 
radiographs of the skull only.92 In 1973, the computed to­
mography scanner was introduced to clinical medicine42 
and was soon used to obtain images of the brain and sella 
turcica.369,78 This was soon followed by the development of 
MR imaging in the late l970s.23'27'38'43'66 The computed to­
mography and MR imaging findings correlated with surgi­
cal findings in 42 and 52% of cases of ACTH-secreting
microadenomas, respectively.17 High field strength MR 
imagers and dynamic imaging techniques have improved 
the sensitivity in recent years.13 Last, the invasive endovas- 
cular technique of inferior petrosal sinus sampling was 
developed,21 yielding very high sensitivity and specificity 
in cases of pituitary-dependent Cushing disease.5,59
The last advances to consider in the recent developments 
in management of Cushing disease are the contributions of 
neurosurgeons. Pituitary surgery was initially attempted in 
1893 by Caton and Paul18 in a patient with acromegaly. It 
soon became apparent to the neurosurgical community, 
however, that pituitary surgery was a morbid endeavor and 
therefore its use was largely abandoned, except in the most 
extreme cases, which were treated with transcranial opera- 
tions.60
The earliest reported successful pituitary surgery for mi­
croadenoma-related Cushing disease was conducted in 
1933 (but not published until 1944),58 yet most patients 
with Cushing syndrome and a pituitary tumor underwent 
sellar radiotherapy and adrenalectomy; the adrenalectomy 
treated the hypercortisolemia and the radiotherapy success­
fully controlled the growth of most of these tumors.14,46 
With improvements in antibiotic therapy and intraoperative 
technology (including instrumentation, operative micros­
copy and microsurgery, and fluoroscopy), transsphenoidal 
pituitary surgery slowly gained acceptance, largely because 
of the work of Jules Hardy.36 As pituitary surgery became 
more widely accepted, it was used successfully to treat 
Cushing disease but was still not considered the standard of 
care into the 1980s. For instance, there was debate over the 
effectiveness of prophylactic sellar irradiation in the pre­
vention of Nelson syndrome.455765 In 1980, Nelson wrote in 
an editorial, “in those patients who fail to be cured ade­
quately by the transsphenoidal approach, irradiation should 
be considered.”70
These advancements associated with improved manage­
ment of Cushing syndrome also apply to the diagnosis and 
treatment of Nelson syndrome. Currently, measurement of 
ACTH is a reliable and routine laboratory investigation that 
is widely available. Even minor elevations in ACTH levels 
can be identified after adrenalectomy, and further investi­
gations can be performed. Serial imaging after treatment 
for Cushing disease is now routine. Initially, the sella was 
imaged only with skull radiography,92 but current MR im­
aging systems can detect small-size tumors.52 Similarly, the 
surgical treatment of Nelson tumors has evolved. The ear­
liest report of pituitary surgery for Nelson syndrome was 
published by Espinoza et al.29 in 1973, who performed sur­
gery in three patients via a transsphenoidal approach and 
were able to normalize the ACTH in two and reduce the 
level in the third patient postoperatively; no more than 
immediate results were reported.
Although the authors of early series found only limited 
success after transsphenoidal pituitary surgery for Nelson 
syndrome (27% success),94 the authors of later reports 
showed somewhat better outcomes (success rate range 
46-80% ).325095 As with other tumors of the pituitary, resid­
ual or recurrent tumors can be treated with stereotactic 
radiosurgery.96
The current treatment paradigm for Cushing disease 
includes aggressive treatment with therapies directed at the 
pituitary tumor. Resection is the primary treatment modal-
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A M E T H O D  F O R  T H E  D E T E R M I N A T I O N  OF 17 
H Y D R O X Y C O R T I C O S T E R O I D S  IN B LO O D : 17- 
H Y D R O X Y C O R T I C O S T E R O N E  IN  T H E  
P E R I P H E R A L  C IR C U L A T IO N *
DON H. NELSON, M .D .f a n d  LEO T . SAM UELS, Ph.D .
From the Department of Biochemistry, University of Utah College of Medicine,
)R EN A L steroid activity has been demonstrated in adrenal venous
blood by means of biologic assay (1, 2). The biologic techniques, al­
though successful in demonstrating the presence of adrenal steroids, have 
been unsatisfactory from a quantitative standpoint and have given little 
information regarding the specific compound being measured. Chemical
posed by Corcoran and Page (3), and by Porter and Silber (4).
The method of Corcoran and Page was found to give high values due to 
the formation of formaldehyde from phospholipids, traces of which could 
not be eliminated even by repeated precipitation with acetone. The color 
reaction of Porter and Silber depends on the formation of phenylhydra- 
zones in acid solution. Under the conditions given, the 17,21-dihydroxy- 
20-ketosteroids showed a strong maximum absorption at 410 m^ when 
several steroid ketones were tested. The purification procedure used with 
plasma, however, was so nonspecific as to. raise the question of the in­
fluence of other compounds on the reaction.
The present communication deals with the development of a method for 
the quantitative estimation of 17-hydroxycorticosteroids in peripheral 
blood, using the color reaction described by Porter and Silber. The chief 
compound measured is apparently 17-hydroxycorticosteronel (5).
F ig. 5. The title page taken from Dr. Nelson’s first series of patients with the postadrenalectomy syndrome, which 
later became known as Nelson syndrome.
Salt Lake City, Utah
methods for the determination of adrenal steroids in blood have been pro-
ity and can lead to biochemical cure in 74 to 78% of 
cases.2086 Reoperation should be considered in cases of 
accessible residual or recurrent tumor, including total hypo­
physectomy.8'61 For unresectable disease (that is, cavernous 
sinus invasion), radiation can be delivered via convention­
al means or using conformal techniques.85 Adrenalectomy 
should be considered only after therapy directed at the pitu­
itary gland has failed. After adrenalectomy, patients must 
be carefully observed with serial MR imaging and labora­
tory investigations. The use of prophylactic sellar irradia­
tion in the cases of persistent hypercortisolemia and 
without the demonstration of pituitary adenoma is contro- 
versial.34
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cortisolemia and tests became available to diagnose the 
cause, the number of patients undergoing adrenalectomy in 
the modern era decreased, and even fewer are developing 
Nelson syndrome. In light of these considerations, we be­
lieve that Nelson syndrome should be reevaluated to deter­
mine the roles of surgery, radiotherapy, and radiosurgery in 
the modern era.
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Appendix: Biography of Dr. Don H. Nelson
Don Nelson was born in Salt Lake City, Utah, in 1925. He attend­
ed the University of Utah where he received his B.A. It was while 
at the University of Utah Medical School that he first became inter­
ested in endocrinology research. Dr. Leo Samuels was the chairman 
of the Department of Biochemistry and had already established 
himself as an expert in steroid biochemistry. Nelson joined Sam­
uels’s laboratory after his internship, and there made substantial 
contributions to clinical adrenal biochemistry and physiology. He 
graduated from medical school in 1947 and completed an internship 
at Milwaukee County Hospital the following year. He then returned 
to the University of Utah and Dr. Samuels’s laboratory as a research 
fellow and, later, became a research assistant professor of biochem­
istry. Nelson was drafted into the Navy in 1952. He was stationed 
in Bethesda, Maryland, where he continued his research at the 
Naval Medical Research Institute.
While in Bethesda, Nelson and Hume developed a method for 
measuring ACTH levels in blood. In 1954, Nelson was discharged 
from the military and moved to Boston to start his residency in 
internal medicine. While at Harvard, he also completed a fellowship 
in endocrinology under Dr. George Thorn, and he was one of the 
first fellows of the Howard Hughes Medical Institute, where he used 
his ACTH assay to study the possible causes of Cushing syndrome. 
Using this assay, Nelson and his colleagues reported the case of “C. 
R.” and the postadrenalectomy syndrome that eventually became 
known as Nelson syndrome. This case report was widely read and 
well received. After completing his training, he joined the faculty of 
the Peter Bent Brigham Hospital and became the director of its 
Clinical Research Center. In 1959 he moved to Los Angeles to
become the chief of endocrinology at the University of Southern 
California, where he established a new clinical research center, 
maintaining his ties to the Howard Hughes Medical Institute. In 
1959, with the support and urging of Dr. Wintrobe, the head of the 
Department of Medicine at the University of Utah, he moved back 
to his hometown of Salt Lake City to head the newly founded 
Department of Medicine at LDS Hospital. He created a strong de­
partment based on clinical and basic research. He also established 
an affiliation with the University of Utah, training successive gen­
erations of medical students, resident physicians, and research fel­
lows. In 1980 he became the head of the Division of Endocrinology 
at the University of Utah. Dr. Nelson’s bibliography speaks for it­
self. He was a leading scientist and clinician in endocrinology. He 
is now retired from the clinical practice of medicine and still lives 
in Salt Lake City. He continues to follow his interests in endocrinol­
ogy and contribute to the body of medical knowledge. He maintains 
an active affiliation with the Division of Endocrinology at “the U” 
and continues to publish in his field. His chief contribution in recent 
years has been the discovery that sphingolipids mediate the bio­
chemical effects of corticosteroids and the harmful effects that we 
associate with Cushing syndrome.35- 77
[Dr. Nelson reviewed the historical aspects o f this paper.]
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